Results 191 to 200 of about 5,456,142 (288)

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source

Proteomic Pathways Linking Type 2 Diabetes Genetic Clusters to Cardiovascular Diseases: A Network Mendelian Randomisation Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Genetic clusters related to Type 2 diabetes (T2D) have differential impact on cardiovascular diseases (CVDs), although the underlying mechanisms, such as proteomic perturbation, remain unexplored. We conducted a network Mendelian randomisation (MR) study to identify proteomic mediators linking T2D genetic clusters and CVDs.
Shuang Liao, Gabriel Chun Yin Sung, Yiwen Liang, Chenxi Li, Shiu Lun Au Yeung   +4 more
wiley   +1 more source

Socioeconomic Factors and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review. [PDF]

Liver Int
Wiering L, Demir M.
europepmc   +1 more source

Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella

Clinical Gastroenterology and Hepatology
Mazen Noureddin, Lai Wei, Laurent Castera, Emmanuel A. Tsochatzis   +3 more
openaire   +3 more sources

Natural history of metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD), which has been the term for non-alcoholic fatty liver disease (NAFLD) since June 2023, represents the most common liver disease worldwide and is a leading cause of liver-related morbidity ...
Papatheodoridis, George V., Lekakis, Vasileios   +1 more
core  

Targeting gut immunity as a therapy for steatotic liver disease. [PDF]

eGastroenterology
Gao RY.
europepmc   +1 more source

Glucose Challenge Test Values Within the Normal Range and Long‐Term Risk of Type 2 Diabetes by Pre‐Pregnancy BMI: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Gestational diabetes (GDM) is the strongest known risk factor for maternal type 2 diabetes. However, little is known about type 2 diabetes risk in women with normal glucose challenge test (GCT) results during pregnancy. We investigated the association between GCT results in the normal range and type 2 diabetes risk, both overall and ...
Yael Barer, Tal Schiller, Maya Nitecki, Gilad Twig, Gabriel Chodick   +4 more
wiley   +1 more source

Effects and Mechanisms of Stevioside on Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Food Sci Nutr
Li K, Zhang C, Kang L, Mu Y, Li Z, Zhang J, Li G.   +6 more
europepmc   +1 more source

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek, Hajnalka Lőrincz, Mariann Harangi, Attila Csaba Nagy   +3 more
wiley   +1 more source

Breast Cancer and Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]

Int J Mol Sci
Nieva-Ramírez DG, Luna-Pérez D, Uribe M, Nuño-Lámbarri N.   +3 more
europepmc   +1 more source